{
    "clinical_study": {
        "@rank": "112594", 
        "acronym": "D-Lay-MS", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.\nIntervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
            }, 
            {
                "arm_group_label": "Vit D", 
                "arm_group_type": "Experimental", 
                "description": "Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.\nIntervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study is to evaluate the efficacy and tolerance of 2 years of\n      treatment with cholecalciferol (vitamin D3) in patients with a clinically isolated syndrome\n      at high risk for MS (CIS)."
        }, 
        "brief_title": "Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The secondary objectives of this study are:\n\n      A. evaluate clinical efficacy: delay to conversion; number of relapses/episodes per year B.\n      evaluate efficacy in terms of resonance imaging parameters (cerebral/spinal MRI) C. evaluate\n      efficacy in terms of  slowing the progression of disability as measured by EDSS score and\n      subscores D. measure and assess cognitive abilities (PASAT) E. evaluate changes in quality\n      of life (EQ5D questionnaires, SF36, and TLS-TLS-QoL10 COPING10), fatigue questionnaire\n      (FSMC) and anxiety / depression questionnaire (HADS) F. evaluate treatment tolerance G. to\n      correlate changes in clinical and imaging parameters with the evolution of serum levels of\n      25(OH)D2 and 25(OH)D3 H. establish a biobank of DNA and RNA from all patients in the study\n      and conduct analyses of gene polymorphisms involved in the metabolism of vitamin D and the\n      HLA system based on the increased levels of vitamin D after supplementation I. establish a\n      biobank of CSF, plasma, blood cells, serum and RNA samples for patients in selected centers\n      for research on prognostic biomarkers of conversion J. establish a biobank consisting of\n      plasma tubes collected for the determination of 25-hydroxy-vitamin D K. Estimate the rate of\n      discordance between the conversion decision made by the study neurologist and the result of\n      the MRI re-interpretation performed at the end of the study as well as the proportion of\n      patients identified a posteriori as as erroneously included according to the centralized\n      reading."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must have given his/her informed and signed consent\n\n          -  The patient must be insured or beneficiary of a health insurance plan\n\n          -  The patient is available for 24 months of follow-up\n\n          -  The patient has had a classic CIS with the past 60 days\n\n          -  Reference cerebro-medullary MRI scheduled within the 60 days after the beginning of\n             symptoms\n\n          -  With MRI (cerebro \u00b1 medullary) showing demyelination according to spatial spread\n             criteria by Swanton (2006):\n\n          -  At least 1 lesion in at least 2 of the 4 following territories: (1) Peri-ventricular;\n             (2) Juxta-cortical; (3) Sub-tentorial; (4) Medullary\n\n          -  No other suspected pathology\n\n          -  Vitamin D level in blood less than 100 nmol / l at the pre-inclusion visit\n\n          -  Women of childbearing potential must use very effective contraception for the\n             duration of the study. A very effective contraceptive method is defined as a method\n             resulting in a low failure rate (that is to say less than 1% per year) when used\n             consistently and correctly, such as implants, injectables, combined oral\n             contraceptives, IUDs, sexual abstinence, or partner with a vasectomy.\n\n        Randomisation stratification criteria:\n\n          -  The patient can also also meet the temporal dissemination criteria defined according\n             to McDonald criteria 2010 (Polman et al., 2011), because this condition is currently\n             not sufficient for prescribing a background treatment: Simultaneous presence of at\n             least one asymptomatic lesion taking on contrast and at least one asymptomatic lesion\n             not taking on contrast after injection of gadolinium\n\n        Exclusion Criteria:\n\n          -  The patient is participating in another study (this criteria does not apply to the\n             POLAR study (RCB 2011-A01269-32); patients included in this study may simultaneously\n             participate in the POLAR study)\n\n          -  The patient is in an exclusion period determined by a previous study\n\n          -  The patient is under judicial protection, under tutorship or curatorship\n\n          -  The patient refuses to sign the consent\n\n          -  It is impossible to correctly inform the patient\n\n          -  The patient is pregnant, parturient, or breastfeeding\n\n          -  Major medical or psychiatric illness that, according to the investigator, would\n             result in the patient running an unnecessary risk or that could affect compliance\n             with the study protocol\n\n          -  Vitamin D insufficiency linked to currently active digestive or more general diseases\n             (celiac disease, inflammatory bowel disease,  intestinal bypass, short bowel\n             syndrome, cirrhosis, nephrotic syndrome, hyperthyroidism, rickets,\n             hypoparathyroidism, cancer, granulomatous diseases and lymphomas)\n\n          -  Moderate or severe renal insufficiency (creatinine clearance less than 60 ml / min)\n\n          -  Epilepsy not adequately controlled by treatment\n\n          -  Any illness requiring chronic treatment with corticosteroids\n\n          -  Patient with osteoporosis or history of osteopenia\n\n          -  Pathology requiring calcium intakes greater than 1 gram per day\n\n          -  Current or past history of hypercalcemia\n\n          -  Medications that affect the metabolism of vitamin D other than corticosteroids; e.g.\n             anticonvulsants [phenobarbital, primidone, phenytoin] rifampicin, isoniazid,\n             ketoconazole, 5-FU and leucovorin, thiazide diuretics.\n\n          -  Situations accompanied by increased vulnerability to hypercalcemia, e.g. arrhythmia\n             or known heart disease, treatment with digitalis, and subjects with nephrolithiasis.\n\n          -  Contraindications to vitamin D3 as mentioned in the documentation for UVEDOSE\n\n          -  Known hypersensitivity to gadolinium and / or known inability to undergo an MRI\n             (pacemaker, osteosynthesis material, intraocular metal splinter, etc ....)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "316", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817166", 
            "org_study_id": "PHRC-N/2012/ET-01", 
            "secondary_id": "2012-005821-59"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vit D", 
                "description": "Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug", 
                "other_name": "Cholecalciferol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Vit D"
                ], 
                "description": "All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.", 
                "intervention_name": "Imaging", 
                "intervention_type": "Other", 
                "other_name": "Cerebro-medullar MRI"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Vit D"
                ], 
                "description": "A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)", 
                "intervention_name": "Lumbar puncture", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Vit D"
                ], 
                "description": "Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.", 
                "intervention_name": "Blood sampling", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Vit D"
                ], 
                "description": "Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.", 
                "intervention_name": "Urine samples", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cholecalciferol", 
            "vitamin D", 
            "immune disease", 
            "clinically isolated syndrome"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amiens Cedex 1", 
                        "country": "France", 
                        "zip": "80054"
                    }, 
                    "name": "CHU d'Amiens - H\u00f4pital Nord"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier Godefroy, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Abdullatif Al Khedr, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on", 
                        "country": "France", 
                        "zip": "25030"
                    }, 
                    "name": "CHU de Besan\u00e7on - H\u00f4pital Jean Minjoz"
                }, 
                "investigator": {
                    "last_name": "Eric Berger, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "CHU de Lyon - H\u00f4pital Pierre Wertheimer"
                }, 
                "investigator": [
                    {
                        "last_name": "Christian Confavreux, MD, PHD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sandra Vukusic, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen Cedex 9", 
                        "country": "France", 
                        "zip": "14033"
                    }, 
                    "name": "CHU de Caen - H\u00f4pital C\u00f4te de Nacre"
                }, 
                "investigator": [
                    {
                        "last_name": "Gilles Defer, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie Derache Belpalme, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63003"
                    }, 
                    "name": "CHU de Clermont Ferrand - H\u00f4pital Gabriel-Montpied"
                }, 
                "investigator": [
                    {
                        "last_name": "Pierre Clavelou, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fr\u00e9d\u00e9ric Thaite, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cornebarrieu", 
                        "country": "France", 
                        "zip": "31700"
                    }, 
                    "name": "Clinique des C\u00e8dres - Capio"
                }, 
                "investigator": {
                    "last_name": "Claude Mekies, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "CHU de Dijon"
                }, 
                "investigator": {
                    "last_name": "Thibault Moreau, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "zip": "38043"
                    }, 
                    "name": "CHU de Grenoble - H\u00f4pital A Michallon"
                }, 
                "investigator": {
                    "last_name": "Olivier Casez, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU de Lille - H\u00f4pital Roger Salengro"
                }, 
                "investigator": [
                    {
                        "last_name": "Patrick Vermersch, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "H\u00e9l\u00e8ne Zephyr, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Olivier Outteryck, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "CHU de Limoges - H\u00f4pital Dupuytren"
                }, 
                "investigator": {
                    "last_name": "Laurent Magy, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lomme Cedex", 
                        "country": "France", 
                        "zip": "59462"
                    }, 
                    "name": "Groupe Hospitalier de l'Institut Catholique de Lille"
                }, 
                "investigator": [
                    {
                        "last_name": "Patrick Hautecoeur, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "C\u00e9cile Donz\u00e9-Parret, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU de Montpellier - H\u00f4pital Gui de Chauliac"
                }, 
                "investigator": [
                    {
                        "last_name": "William Camu, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bertrand Carlander, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mahmoud Charif, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre Labauge, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France", 
                        "zip": "54035"
                    }, 
                    "name": "CHU de Nancy - H\u00f4pital Central"
                }, 
                "investigator": [
                    {
                        "last_name": "Marc Debouverie, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie Pittion-Vouyovitch, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU de Nantes - H\u00f4tel-Dieu"
                }, 
                "investigator": [
                    {
                        "last_name": "Sandrine Wiertlewski, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "David Laplaud, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06002"
                    }, 
                    "name": "CHU de Nice - H\u00f4pital Pasteur"
                }, 
                "investigator": {
                    "last_name": "Christine Lebrun-Fresnay, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes Cedex 9", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "CHU de N\u00eemes - H\u00f4pital Universitaire Car\u00e9meau"
                }, 
                "investigator": [
                    {
                        "last_name": "Eric Thouvenot, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Giovanni Castelnovo, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75019"
                    }, 
                    "name": "Fondation Ophtalmologique Adolphe Rothschild"
                }, 
                "investigator": {
                    "last_name": "Olivier Gout, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "APHP - H\u00f4pital Tenon"
                }, 
                "investigator": {
                    "last_name": "Bruno Stankoff, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perpignan", 
                        "country": "France", 
                        "zip": "66046"
                    }, 
                    "name": "CH de Perpignan - H\u00f4pital Saint Jean"
                }, 
                "investigator": [
                    {
                        "last_name": "Nicolas Gaillard, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anais Dutray, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quimper", 
                        "country": "France", 
                        "zip": "29107"
                    }, 
                    "name": "CH de Cornouaille - Site Quimper - H\u00f4pital Laennec"
                }, 
                "investigator": {
                    "last_name": "Marc Coustans, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51092"
                    }, 
                    "name": "CHU de Reims - H\u00f4pital Maison Blanche"
                }, 
                "investigator": {
                    "last_name": "Ayman Tourbah, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU de Rennes - H\u00f4pital PontChaillou"
                }, 
                "investigator": [
                    {
                        "last_name": "Gilles Edan, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emmanuelle Le Page, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "V\u00e9ronique Deburghgraeve, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76031"
                    }, 
                    "name": "CHU de Rouen - H\u00f4pital Charles Nicolle"
                }, 
                "investigator": [
                    {
                        "last_name": "Didier Hannequin, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bertrand Bourre, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Germain-en-Laye", 
                        "country": "France", 
                        "zip": "78100"
                    }, 
                    "name": "CH de Poissy - Saint-Germain-en-Laye"
                }, 
                "investigator": {
                    "last_name": "Olivier Heinzlef, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Priest en Jarez", 
                        "country": "France", 
                        "zip": "42270"
                    }, 
                    "name": "CHU de Saint Etienne - H\u00f4pital Nord"
                }, 
                "investigator": {
                    "last_name": "Jean-Philippe Camdessanch\u00e9, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saumur Cedex", 
                        "country": "France", 
                        "zip": "49403"
                    }, 
                    "name": "CH de Saumur"
                }, 
                "investigator": {
                    "last_name": "Richard Devy, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg Cedex", 
                        "country": "France", 
                        "zip": "67091"
                    }, 
                    "name": "CHRU de Strasbourg - H\u00f4pital Civil"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me De S\u00e8ze, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHRU de Toulouse - H\u00f4pital Purpan"
                }, 
                "investigator": {
                    "last_name": "David Brassat, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "CHRU de Tours - H\u00f4pital Bretonneau"
                }, 
                "investigator": [
                    {
                        "last_name": "Philippe Corcia, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Marie Guennoc, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Versailles", 
                        "country": "France", 
                        "zip": "78000"
                    }, 
                    "name": "CH de Versailles - H\u00f4pital Mignot"
                }, 
                "investigator": [
                    {
                        "last_name": "Fernando Pico, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Chantal Nifle, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.", 
        "other_outcome": [
            {
                "measure": "DNA sample (blood sample) for biobank", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Hemogram", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "alanine amino transferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "aspartate aminotransferase serum levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "alkaline phosphatase serum levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum albumin levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum urea levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum bilirubin levels", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "serum electrolyte panel", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }
        ], 
        "overall_contact": {
            "email": "eric.thouvenot@chu-nimes.fr", 
            "last_name": "Eric Thouvenot, MD, PhD", 
            "phone": "+33.(0)4.66.68.32.61"
        }, 
        "overall_contact_backup": {
            "email": "carey.suehs@chu-nimes.fr", 
            "last_name": "Carey M Suehs, PhD", 
            "phone": "+33.(0)4.66.68.67.88"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
                "last_name": "Eric Thouvennot, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
                "last_name": "Eric Thouvenot, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Conversion to MS according to criteria described by McDonald  (Polman et al 2005)", 
            "measure": "Conversion to MS yes/no", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of relapse episodes (number per year)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "number of new brain lesions found in FLAIR MRI or medullary lesions found in T2 MRI", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Number of FLAIR brain lesions that increase in size", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Number of FLAIR brain lesions that increase in size", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Number of FLAIR brain lesions that increase in size", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "qualitative variable: 0, 1, or >1", 
                "measure": "Number of new T1 lesions taking on Gadolinium highlighting", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "qualitative variable: 0, 1, or >1", 
                "measure": "Number of new T1 lesions taking on Gadolinium highlighting", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "qualitative variable: 0, 1, or >1", 
                "measure": "Number of new T1 lesions taking on Gadolinium highlighting", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Number of hyposignal T1 lesions (black holes)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Number of hyposignal T1 lesions (black holes)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Number of hyposignal T1 lesions (black holes)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Lesional burden in mm^3 for each cerebral MRI", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Lesional burden in mm^3 for each cerebral MRI", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Lesional burden in mm^3 for each cerebral MRI", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Exact number (semiautomatic measure)", 
                "measure": "Total number of Gadolinium highlighted lesions on T1 images", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Exact number (semiautomatic measure)", 
                "measure": "Total number of Gadolinium highlighted lesions on T1 images", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Exact number (semiautomatic measure)", 
                "measure": "Total number of Gadolinium highlighted lesions on T1 images", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "mm^3", 
                "measure": "Normalized cerebral volume (SIENAX) obtained from a T13D sequence", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "mm^3", 
                "measure": "Normalized cerebral volume (SIENAX) obtained from a T13D sequence", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "mm^3", 
                "measure": "Normalized cerebral volume (SIENAX) obtained from a T13D sequence", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Change in global cerebral volume (mm^3)", 
                "safety_issue": "No", 
                "time_frame": "baseline versus 24 months"
            }, 
            {
                "measure": "EDSS score, including all subscores", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "EDSS score, including all subscores", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "EDSS score, including all subscores", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "EDSS score, including all subscores", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "EDSS score, including all subscores", 
                "safety_issue": "No", 
                "time_frame": "after second MS episode (1st relapse)(maximum 24 months)"
            }, 
            {
                "measure": "score for the PASAT 3 seconds section of the MSFC score", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "score for the PASAT 3 seconds section of the MSFC score", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "score for the PASAT 3 seconds section of the MSFC score", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "score for the PASAT 3 seconds section of the MSFC score", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "score for the PASAT 3 seconds section of the MSFC score", 
                "safety_issue": "No", 
                "time_frame": "after second MS episode (1st relapse)(maximum 24 months)"
            }, 
            {
                "measure": "EQ5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "EQ5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "EQ5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "EQ5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "SF36 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "SF36 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "SF36 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "SF36 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "FSMC fatigue scale", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "FSMC fatigue scale", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "FSMC fatigue scale", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "FSMC fatigue scale", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "TLS-QOL10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "TLS-QOL10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "TLS-QOL10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "TLS-QOL10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "TLS-Coping10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "TLS-Coping10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "TLS-Coping10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "TLS-Coping10 questionnaire", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "HADS questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "HADS questionnaire", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "HADS questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "HADS questionnaire", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Presence/absence of adverse events the severity of which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades I, II, III, IV, V.", 
                "measure": "Presence/absence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "25(OH)D2+D3 serum level (nmol/l)", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Calciuria/creatinuria", 
                "safety_issue": "No", 
                "time_frame": "upon conversion to MS (maximum 24 months)"
            }, 
            {
                "description": "The number of days that pass from the beginning of treatment to conversion to MS according to McDonald 2005 criteria (Polman et al 2005)", 
                "measure": "Delay until conversion to MS", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de N\u012bmes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de N\u012bmes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}